#Canada #Montreal #GSK #Biodextris #Behzad Mahdavi

Biodextris Appoints Dr. Behzad Mahdavi as Executive Chairman for Global Growth

On June 4, 2025, Biodextris, a prominent Contract Development and Manufacturing Organization (CDMO) with deep roots in the biologics and vaccine sectors formerly operated by GSK, made a significant announcement concerning its leadership structure. The firm has welcomed Dr. Behzad Mahdavi as the new Executive Chairman, a move expected to propel the company's international expansion efforts in the biopharmaceutical field.

Dr. Mahdavi, who also takes on the role of Chief Commercial Officer, brings a wealth of experience exceeding 25 years within the CDMO and Contract Research Organization (CRO) landscapes. His past leadership roles at industry players such as Lonza, Catalent Pharma Solutions, and Ginkgo Bioworks have established him as a seasoned expert in commercial innovation and global market strategies. This appointment is seen as a strategic pivot for Biodextris, aligning their operational capabilities with the increasing demand for sophisticated biopharmaceutical solutions.

"With our scientific heritage and a state-of-the-art GMP facility, Biodextris is uniquely positioned to assist companies in overcoming the challenges associated with scaling complex biologics and advanced therapeutic modalities," Dr. Mahdavi stated. His vision centers around cultivating Biodextris into a preferred partner for innovative pharmaceutical and cell engineering companies, enhancing the reliability and speed of their product development processes.

Dr. Mahdavi’s leadership comes at a strategic time, as Biodextris is in the midst of expanding its versatile GMP facility, which is critical for accommodating the growing requirements of biologics development. Cédric Héroux, the CEO of Biodextris, expressed enthusiasm about the addition of Dr. Mahdavi, highlighting his commercial acumen which is crucial for the company’s ongoing growth trajectory.

The transition indicates a shift of responsibilities for Patrick Monpetit, the former Chairman of the Board, who will now serve as Vice-Chairman, continuing to play an active role in supporting the company's ambitions.

This leadership transition is particularly relevant in today’s biopharmaceutical market, where speed and agility in development are essential. Biodextris is committed to reinforcing its position as a reliable partner in the international landscape of biologics development, capitalizing on its scientific expertise and advanced manufacturing capabilities.

To gain further insights into Dr. Mahdavi's vision and the company's expanding service offerings, attendees are encouraged to meet him and the Biodextris team at the upcoming BIO International Convention. This forum presents a valuable opportunity for industry stakeholders to explore the company’s forward-looking strategies and innovative solutions for biologics manufacturing.

About Biodextris

Biodextris operates as a full-service CDMO, delivering integrated biomanufacturing solutions to the biopharmaceutical industry. With a focus on biologics, vaccines, and cell and gene therapies, the company combines unparalleled scientific knowledge with cutting-edge infrastructure to support clients from the early stages of development through to commercial manufacturing. Reliability, flexibility, and speed remain at the core of its service offerings, positioning Biodextris as a trustworthy partner in the evolving landscape of biopharmaceuticals.